Arca
Skip to content
Tools
Tools

Hepatitis D

Drug research and approvals for hepatitis D: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 20 studies of hepatitis D are recruiting on ClinicalTrials.gov, Health Canada has authorized 3 drug trials for it since 2013, FDA has 1 approved and 1 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 20
  • Trials authorized in Canada: 3
  • FDA orphan approvals: 1
  • EU medicines: 1

Recruiting now

Newest start dates first, of 20 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Phase 3 6

Phase 2 12 of 13

Phase 1 or earlier 1

  • NivolumabProgrammed cell death protein 1 inhibitor

How its trials ended

85 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 18 whose ending is known, 39% met their primary endpoint, 11% missed it and 50% stopped early.

  • Ongoing3440%
  • Completed, result not reported2428%
  • Status unknown911%
  • Met its primary endpoint78%
  • Stopped: other or unclear56%
  • Stopped: sponsor or business decision34%
  • Missed its primary endpoint22%
  • Stopped: enrollment or feasibility11%

Trials authorized in Canada

Newest first; search them all in Canada trials
May 8, 2025A global, randomized, open-label, multicenter, phase 2b/3 trial evaluating BJT-778 vs delayed treatment for the treatment of chronic hepatitis delta infection…Brelovitug (BJT-778)Mirum PharmaceuticalsOngoing
Mar 20, 2025A phase 3 randomized, open-label study to evaluate the efficacy and safety of tobevibart+elebsiran combination therapy in participants with chronic hdv…Tobevibart (VIR-3434) / Elebsiran (VIR-2218)Vir Biotechnology, Inc.Ongoing
Mar 1, 2019A phase 3, matrix design, partially double-blind, randomized study of the efficacy and safety of 50 mg lonafarnib / 100 mg ritonavir bid with and without 180…Lonafarnib/ Ritonavir/ Peginterferon ALFA-2AEiger Biopharmaceuticals, IncClosed

FDA orphan designations

Approved first, then open designations, newest first
May 22, 2026HepcludexTreatment of chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or with compensated cirrhosisGilead Sciences, Inc.Approved
Jun 14, 2012Interferon-alpha secreting autologous micro-organ tissue…Treatment of chronic hepatitis DMedgenics, Inc.Designated

Medicines authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Jul 31, 2020HepcludexBulevirtide · orphanGilead Sciences Ireland UCEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.